New Drug Development Platform
Centered on amniotic fluid stem cells (AFSCs) and exosomes, U-NEURONhasbuilt a regenerative medicine drug development platform focused on neural repair and tissue regeneration. Targeting major unmet medical needs that conventional treatments cannot resolve, the platform pioneers innovative therapeutic mechanisms.
This platform will serve as the company’s key growth engine toward achieving NT$10 billion in revenue.
Core R&D Pipeline
UA002 | Erectile Dysfunction (ED)
Promotes neural and vascular regeneration and repair using amniotic fluid stem cells
- Overcomes the limitations of conventional symptomatic treatments
- Rebuilds corpus cavernosum nerve and vascular networks
Restores natural physiological function rather than providing temporary stimulation👉 Specially targets:
- • Patients with nerve damage following prostate surgery
- • Complex neurovascular damage caused by diabetes
- • Non-responders to traditional PDE-5 inhibitors (up to 30–50%)
UB003 | Dry Eye Disease / Neurotrophic Keratitis
Exosome-directed ophthalmic regenerative therapy
- Promotes corneal nerve repair
- Alleviates chronic inflammation and dry eye symptoms
- Targets rare diseases and refractory patients
Current Status:
- CMC / Preclinical / Pre-IND (PIND) Preparation
- Demonstrated a favorable safety profile and positive efficacysignals
Core Technical Advantages
Unlike conventional treatments that provide only short-term effects:
Comparison Item
Conventional Treatment (e.g. Viagra)
UA002 (Amniotic Fluid Stem Cell Platform)
Core Mechanism
Vasodilation (symptomatic relief)
Neural + Vascular Regeneration (root-cause repair)
Administration Method
Requires daily / prior-use dosing
Long-lasting effect from single treatment
Physiological Significance
Potential side effects
Core mechanism based on cellular repair
International Clinical and Academic Team
This platform is co-led by top global experts in urology and regenerative medicine:
- Authority in molecular urology at UCSF
- Key scientist team involved in discovering the physiological mechanism of Viagra
- Principal Investigator for Taiwan clinical trials (Phase 1/2a)
- Chief Editor of international journals and president-level expert of academic societies
Clinical and Regulatory Progress
UA002 Clinical Development Roadmap
| 2024 | 2025 – 2026 | 2027 |
|---|---|---|
|
Phase 1 Completion (Safety Established)
|
TFDA & CDE Dual-Track ExpeditedRegulatory Guidance
|
Phase 2b
Double-Blind Trial (Efficacy Validation) |
|
👉Policy Support
👉 Accelerated Review Advantage 👉 High Success Potential |
||
Market Potential & Commercial Value
Erectile Dysfunction (ED) Market
Target Audience & Market Potential
Core Value Focus:
Targeting patient populations with limited benefit from conventional therapies to capture a high-growth, underserved market segment.